A genetically engineered herpes virus may offer a new and effective treatment for advanced melanoma, providing hope for ...

Vaccination against herpes zoster is associated with lower risks for heart disease, dementia, and mortality among adults aged 50 years and older.

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of ...

There is more evidence that shingles vaccination significantly decreases the risk for heart disease, dementia and death among ...

The researchers found that the weighted incidence rate was 51.90 and 58.41 per 100,000 person-years in individuals initiating SGLT-2 inhibitors and sulfonylureas, respectively.

Breakthrough cryo-EM structures expose multiple drug targets in an essential HSV-1 replication protein.An international ...

Shingles vaccine recipients who had a breakthrough infection experienced no reduction in all-cause dementia compared with those who received a pneumonia vaccine. They trended toward fewer post-zoster ...

Results from the trial's first year were reported at the 2024 ACR meeting, and they persuaded the FDA to approve the drug for ...

Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir ...